{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:13:37Z","timestamp":1790874817746,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K01DK116929"],"award-info":[{"award-number":["K01DK116929"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["F31AI179292"],"award-info":[{"award-number":["F31AI179292"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Epidemiology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.annepidem.2026.110074","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:14:33Z","timestamp":1773159273000},"page":"110074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation"],"prefix":"10.1016","volume":"117","author":[{"given":"Amy","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Greener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Kileel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Bor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem DF","family":"Venter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro T.","family":"Pisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor J.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana T.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4238-0200","authenticated-orcid":false,"given":"Mhairi","family":"Maskew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.annepidem.2026.110074_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19138125","article-title":"The HIV epidemic in South Africa: key findings from 2017 national population-based survey","volume":"19","author":"Zuma","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.annepidem.2026.110074_bib2","unstructured":"UNAIDS. South Africa 2022 HIV and AIDS Estimates.; 2022."},{"issue":"2","key":"10.1016\/j.annepidem.2026.110074_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/QAI.0000000000002927","article-title":"The effect of HIV programs in South Africa on national HIV incidence trends, 2000\u20132019","volume":"90","author":"Johnson","year":"2022","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib4","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.20.1.21902","article-title":"Twelve-year mortality in adults initiating antiretroviral therapy in South Africa","volume":"20","author":"Cornell","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.annepidem.2026.110074_bib5","unstructured":"Republic of South Africa National Department of Health. Fast Tracking Implementation of the 90-90-90 Strategy for HIV, through Implementatin of the Universal Test and Treat (UTT) and Same Day Antiretroviral Therapy (ART) Initiation for HIV Positive Patients (Circular).; 2017."},{"key":"10.1016\/j.annepidem.2026.110074_bib6","unstructured":"Republic of South Africa National Department of Health. Implementation of Universal Test and Treat Strategy for HIV Positive and Differentiated Care for Stable Patients.; 2016. \u3008https:\/\/connect.emailsrvr.com\/owa\/attachment.ashx?attach\u3009."},{"key":"10.1016\/j.annepidem.2026.110074_bib7","series-title":"2019 ART Clinical Guidelines for the Management of HIV in Adults, Pregnancy, Adolescents, Children, Infants and Neonates","author":"Republic of South Africa National Department of Health","year":"2020"},{"issue":"3","key":"10.1016\/j.annepidem.2026.110074_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae007","article-title":"Final 192-week efficacy and safety results of the advance trial, comparing 3 first-line antiretroviral regimens","volume":"11","author":"Sokhela","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.annepidem.2026.110074_bib9","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"issue":"8","key":"10.1016\/j.annepidem.2026.110074_bib10","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s12981-016-0115-x","article-title":"Dolutegravir (DTG, S\/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials","volume":"13","author":"Jiang","year":"2016","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.annepidem.2026.110074_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102255","article-title":"The burden of non-communicable diseases among people living with HIV in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"65","author":"Moyo-Chilufya","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.annepidem.2026.110074_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25364","article-title":"antiretroviral therapy and non-communicable diseases in sub-Saharan Africa: empirical evidence from 44 countries over the period 2000\u20132016","volume":"22","author":"Coetzee","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/QAI.0000000000000257","article-title":"HIV and non-communicable cardiovascular and pulmonary diseases in low-and middle-income countries in the ART era: what we know and best directions for future research","volume":"67","author":"Bloomfield","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"10.1016\/j.annepidem.2026.110074_bib15","doi-asserted-by":"crossref","first-page":"e967","DOI":"10.1016\/S2214-109X(21)00176-5","article-title":"Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study","volume":"9","author":"Wong","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.annepidem.2026.110074_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25012","article-title":"High prevalence of HIV and non-communicable disease (NCD) risk factors in rural KwaZulu-Natal, South Africa","volume":"20","author":"van Heerden","year":"2017","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"10.1016\/j.annepidem.2026.110074_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-8587(16)30110-3","article-title":"& Endocrinology. HIV and NCDs: the need to build stronger health systems","volume":"4","author":"The Lancet Diabetes","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.annepidem.2026.110074_bib18","article-title":"Responding to the Challenge of Non-Communicable Diseases","year":"2019","journal-title":"UN Interag Task Force Prev Control NCDs"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-39828-6","article-title":"Non-communicable disease comorbidities in HIV patients: diabetes, hypertension, heart disease, and obstructive sleep apnea as a neglected issue","volume":"13","author":"Hadavandsiri","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1477-7525-5-52","article-title":"Multimorbidity and quality of life: a closer look","volume":"5","author":"Fortin","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.annepidem.2026.110074_bib21","article-title":"Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus","volume":"10","author":"Hirigo","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.annepidem.2026.110074_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101836","article-title":"Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa","volume":"57","author":"Brennan","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"issue":"12","key":"10.1016\/j.annepidem.2026.110074_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab537","article-title":"Assessment of obesity and cardiometabolic status by integrase inhibitor use in REPRIEVE: a propensity-weighted analysis of a multinational primary cardiovascular prevention cohort of people with human immunodeficiency virus","volume":"8","author":"Kileel","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib25","doi-asserted-by":"crossref","DOI":"10.4102\/sajhivmed.v23i1.1452","article-title":"Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV","volume":"23","author":"Mondleki","year":"2022","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.annepidem.2026.110074_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/IBPC.S403023","article-title":"Prevalence of and factors associated with hypertension among adults on dolutegravir-based antiretroviral therapy in uganda: a cross sectional study","volume":"16","author":"Mutebi","year":"2023","journal-title":"Integr Blood Press Control"},{"issue":"2","key":"10.1016\/j.annepidem.2026.110074_bib27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/ije\/dys029","article-title":"Cohort profile: the themba lethu clinical Cohort, johannesburg, South Africa","volume":"42","author":"Fox","year":"2013","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.annepidem.2026.110074_bib28","unstructured":"Republic of South Africa National Department of Health. National User Guide on the Prevention and Treatment of Hypertension in Adults at the PHC Level 2021.; 2021."},{"key":"10.1016\/j.annepidem.2026.110074_bib29","doi-asserted-by":"crossref","unstructured":"Robins J.M., Ngel Hern\u00e1n M.A.\u00b4, Brumback B. Marginal Structural Models and Causal Inference in Epidemiology.; 2000.","DOI":"10.1097\/00001648-200009000-00011"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.annepidem.2026.110074_bib31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: A review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"issue":"9-10","key":"10.1016\/j.annepidem.2026.110074_bib33","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/sim.689","article-title":"Multiple imputation of public health research","volume":"20","author":"Zhou","year":"2001","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.annepidem.2026.110074_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.6000\/1929-6029.2015.04.03.7","article-title":"Multiple Imputation by Fully Conditional Specification for Dealing with Missing Data in a Large Epidemiologic Study","volume":"4","author":"Liu","year":"2015","journal-title":"Int J Stat Med Res"},{"key":"10.1016\/j.annepidem.2026.110074_bib35","unstructured":"Statistical Analysis System Institute. SAS\/STAT \u00ae 14.1 User\u2019s Guide The MI Procedure.; 2015."},{"key":"10.1016\/j.annepidem.2026.110074_bib36","unstructured":"Yuan Y.C. Multiple Imputation for Missing Data: Concepts and New Development."},{"issue":"2","key":"10.1016\/j.annepidem.2026.110074_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2242250","article-title":"Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study","volume":"55","author":"Hirigo","year":"2023","journal-title":"Ann Med"},{"issue":"7","key":"10.1016\/j.annepidem.2026.110074_bib38","doi-asserted-by":"crossref","first-page":"E2153","DOI":"10.1093\/cid\/ciaa1219","article-title":"Efavirenz Pharmacogenetics and weight gain following switch to integrase inhibitor\u2013containing regimens","volume":"73","author":"Leonard","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.annepidem.2026.110074_bib39","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: Risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annepidem.2026.110074_bib40","article-title":"Body weight changes in people living with HIV starting dolutegravir versus efavirenz-based regimens in a large cohort in rural Tanzania","author":"Weisser","year":"2024","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib41","doi-asserted-by":"crossref","DOI":"10.4102\/sajhivmed.v24i1.1500","article-title":"Weight gain on dolutegravir: association is not the same as causation","volume":"24","author":"Maartens","year":"2023","journal-title":"South Afr J HIV Med"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086919","article-title":"Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes","volume":"9","author":"Mukonzo","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.annepidem.2026.110074_bib43","doi-asserted-by":"crossref","first-page":"e3902","DOI":"10.1093\/cid\/ciaa1073","article-title":"CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz","volume":"73","author":"Griesel","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.annepidem.2026.110074_bib44","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/QAI.0000000000002650","article-title":"Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV","volume":"87","author":"Huang","year":"2021","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.annepidem.2026.110074_bib45","doi-asserted-by":"crossref","first-page":"26216","DOI":"10.1002\/jia2.26216","article-title":"Body weight and blood pressure changes on dolutegravir-, efavirenz-or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study","volume":"27","author":"Shamu","year":"2024","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"10.1016\/j.annepidem.2026.110074_bib46","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/cid\/ciad297","volume":"77","author":"Sempere","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.annepidem.2026.110074_bib47","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/hiv.13524","article-title":"Characterizing blood pressure trajectories in people living with HIV following antiretroviral therapy: a systematic review","volume":"24","author":"Drago","year":"2023","journal-title":"HIV Med"},{"issue":"12","key":"10.1016\/j.annepidem.2026.110074_bib48","article-title":"Short-term increase in risk of overweight and concomitant systolic blood pressure elevation in treatment-Na\u00efve Persons starting INSTI-based antiretroviral therapy","volume":"6","author":"Galdamez","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"17","key":"10.1016\/j.annepidem.2026.110074_bib49","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.annepidem.2026.110074_bib50","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/CIRCULATIONAHA.107.183885","article-title":"Treatment of hypertension in the prevention and management of ischemic heart disease","volume":"115","author":"Rosendorff","year":"2007","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.annepidem.2026.110074_bib51","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000207","article-title":"Treatment of hypertension in patients with coronary artery disease","volume":"131","author":"Rosendorff","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.annepidem.2026.110074_bib52","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1161\/HYPERTENSIONAHA.123.20788","article-title":"Systolic blood pressure and cardiovascular risk: straightening the evidence","volume":"80","author":"McCarthy","year":"2023","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.annepidem.2026.110074_bib53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0002-9149(99)00635-9","article-title":"Elevated systolic blood pressure as a cardiovascular risk factor","volume":"85","author":"Kannel","year":"2000","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.annepidem.2026.110074_bib54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11906-014-0489-x","article-title":"Cardiovascular risks associated with diastolic blood pressure and isolated diastolic hypertension","volume":"16","author":"Li","year":"2014","journal-title":"Curr Hypertens Rep"},{"issue":"22","key":"10.1016\/j.annepidem.2026.110074_bib55","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1161\/CIRCULATIONAHA.119.044838","article-title":"Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults","volume":"141","author":"Lee","year":"2020","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.annepidem.2026.110074_bib56","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/09564624221129410","article-title":"The risk of hyperglycemia associated with use of dolutegravir among adults living with HIV in Kampala, Uganda: a case-control study","volume":"33","author":"Namara","year":"2022","journal-title":"Int J STD AIDS"},{"issue":"6","key":"10.1016\/j.annepidem.2026.110074_bib57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11906-022-01183-8","article-title":"Sex differences in the prevalence, outcomes and management of hypertension","volume":"24","author":"Connelly","year":"2022","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"10.1016\/j.annepidem.2026.110074_bib58","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s00125-023-05891-x","article-title":"Sex differences in type 2 diabetes","volume":"66","author":"Kautzky-Willer","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.annepidem.2026.110074_bib59","article-title":"Switch to integrase strand transfer inhibitors during the menopausal transition is associated with accelerated body composition change in women with human immunodeficiency virus","volume":"1","author":"Abelman","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110074_bib60","first-page":"573","article-title":"Adverse changes in body composition during the menopausal transition and relation to cardiovascular risk: a contemporary review","volume":"3","author":"Kodoth","year":"2022","journal-title":"Women\u2019s Health Rep (N Rochelle)"},{"issue":"7","key":"10.1016\/j.annepidem.2026.110074_bib61","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/gme.0b013e31824cfc0f","article-title":"Age at menopause and menopause-related symptoms in human immunodeficiency virus-infected Thai women","volume":"19","author":"Boonyanurak","year":"2012","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.annepidem.2026.110074_bib62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1258\/ijsa.2010.010187","article-title":"Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohort","volume":"22","author":"de Pommerol","year":"2011","journal-title":"Int J STD AIDS"},{"issue":"6","key":"10.1016\/j.annepidem.2026.110074_bib63","doi-asserted-by":"crossref","first-page":"765.e1","DOI":"10.1016\/j.ajog.2014.12.040","article-title":"Predictors of early menopause in HIV-infected women: A prospective cohort study","volume":"212","author":"Calvet","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.annepidem.2026.110074_bib64","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1086\/497270","article-title":"HIV infection, drug use, and onset of natural menopause","volume":"41","author":"Schoenbaum","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10.1016\/j.annepidem.2026.110074_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191911899","article-title":"Evaluating the impact of the COVID-19 pandemic on accessing HIV services in South Africa: a systematic review","volume":"19","author":"Jardim","year":"2022","journal-title":"Int J Environ Res Public Health"}],"container-title":["Annals of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047279726000724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047279726000724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:16:39Z","timestamp":1779336999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1047279726000724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":65,"alternative-id":["S1047279726000724"],"URL":"https:\/\/doi.org\/10.1016\/j.annepidem.2026.110074","relation":{},"ISSN":["1047-2797"],"issn-type":[{"value":"1047-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation","name":"articletitle","label":"Article Title"},{"value":"Annals of Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annepidem.2026.110074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110074"}}